Bio-Rad Introduces new Pro-Human Diabetes Assay Panel
News Jun 24, 2008
Bio-Rad Laboratories, Inc. has announced new Bio-Plex Pro™ Human Diabetes Assay Panels for Bio-Rad’s Bio-Plex® suspension array system.
Offered as one multiplex and two singleplex assays designed to achieve optimal working assay ranges, the new pro-human diabetes assay can deliver accurate and reproducible multiplex measurements of human diabetes and obesity markers, the company claims.
• The pro-human assay panel consists of a premixed 12-plex of analytes (C-Peptide, ghrelin, GIP, and visfatin) thataGLP-1, glucagon, IL6, insulin, leptin, PAi-1, resistin, TNF- work with magnetic beads, pre-blended detection antibodies, standards and controls. The singleplex assays (adiponectin and adipsin) may be mixed together to form a 2-plex assay.
• The reagent kit includes an assay buffer, wash buffer, streptavidin-PE, 96-well filter plate, sealing tape, and panel specific instructions required to prepare assays and acquire data.
• The diluents kit can enable the researcher to choose the appropriate diluents kit for diluting samples, standards and controls.
All three Bio-Plex pro-human diabetes assays were validated using real patient samples.
Abzena Selects Sartorius Stedim Biotech to Equip its US Based Development and Manufacturing SitesNews
Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, has selected Sartorius Stedim Biotech as its preferred equipment supplier in the U.S.READ MORE
3D Spheroids Help Scientists Discover Smarter Cancer DrugsNews
An innovative new method to screen for potential cancer drugs. The technique makes use of tiny, three-dimensional ball-like aggregates of cells called spheroids. These structures can be used to interrogate hundreds or even thousands of compounds rapidly using a technique called high throughput screening.READ MORE
Emergex Awarded Innovate UK Grant to Progress its Universal and Pandemic Flu VaccineNews
Emergex Vaccines Holding Limited, a biotechnology company pioneering a new approach to vaccine development in the field of infectious diseases, announces that Innovate UK, the UK’s innovation agency, has awarded the company a grant of £979,318 to progress its universal flu vaccine programme through preclinical development.READ MORE
Comments | 0 ADD COMMENT
World Congress on Bio-organic and Medicinal Chemistry
Nov 12 - Nov 13, 2018